CDC Authorizes Novavax COVID-19 Vaccine as Booster Dose



Following the Food and Drug Administration’s Emergency Use Authorization, CDC’s Director Rochelle P. Walensky, MD, MPH, signed a decision memo allowing Novavax monovalent COVID-19 boosters for adults


A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in people ages 18 years and older who completed any FDA-approved or FDA-authorized primary series, have not received any previous booster dose(s), and are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. The Novavax booster dose is to be given at least six months after completion of a primary series of COVID-19 vaccine.


According to CDC data, 49.6% of the total booster-eligible population has not yet received a booster dose. Offering another vaccine option may help to increase COVID-19 booster vaccination rates among adults.


Impact on IIS

The Clinical Decision Support for Immunization (CDSi) rules are currently being developed and reviewed. The draft version will be released soon, and the official version will become available shortly after publication of the Morbidity and Mortality Weekly Report.


The Advisory Committee on Immunization Practices (ACIP) is meeting today and tomorrow to discuss pneumococcal, chikungunya, COVID-19, polio, RSV, meningococcal, influenza, dengue, and monkeypox vaccines. Votes are expected on pneumococcal vaccine, COVID-19 vaccine for the Vaccines for Children (VFC) program, and 2023 immunization schedule revisions. A summary is forthcoming, as part of our ongoing commitment to share important decisions and recommendations with you. 

American Immunization Registry Association 1717 Pennsylvania Avenue NW, Suite 1025, Washington, District of Columbia 20006, United States 202.522.0208

By accepting you will be accessing a service provided by a third-party external to